Comparative pharmacokinetics and metabolism of levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog

被引:51
作者
Benedetti, MS
Coupez, R
Whomsley, R
Nicolas, JM
Collart, P
Baltes, E
机构
[1] UCB Bioprod SA, Pharma Sector, Dept Global Prod Safety & Metab, F-92003 Nanterre, France
[2] UCB Bioprod SA, Pharma Sector, Dept Global Prod Safety & Metab, B-1420 Braine lAlleud, Belgium
关键词
D O I
10.1080/0049825042000196749
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1. The pharmacokinetics and metabolism of C-14-levetiracetam, a new anti-epileptic agent, in mouse, rat, rabbit and dog after a single oral dose were investigated. Moreover, the in vitro hydrolysis of levetiracetam to its major carboxylic metabolite by rat tissue homogenates was investigated to identify tissues involved in the production of the metabolite. Data are also presented on the induction of the enzyme(s) involved in levetiracetam hydrolysis in the rat. 2. Levetiracetam was rapidly and almost completely absorbed. The unchanged drug accounted for a very high percentage of plasma radioactivity. Levetiracetam did not bind to plasma proteins. Although brain radioactivity concentrations were lower than those of whole blood at early time points, brain-to-blood ratios increased over time. The predominant route of elimination of total C-14 was excretion via urine, accounting for about 81, 93, 87 and 89% of the dose in the mouse, rat, rabbit and dog, respectively. Consequently, levetiracetam was poorly metabolized. It was submitted in vivo to hydrolysis and/or oxidation. Hydrolysis of the amide function of levetiracetam produced the corresponding acid. However, levetiracetam could also be oxidized at positions 3 and 4 of the 2-oxopyrrolidine ring. Finally, the compound and the corresponding acid metabolite could be oxidized at position 5 of the 2-oxopyrrolidine ring and then hydrolysed with the opening of the ring. 3. All the investigated rat tissues (liver, kidney, lung, brain, small intestine mucosa) had the potential to produce the acid metabolite. By contrast, the acid was undetectable following incubation of levetiracetam with buffer alone or heat-denaturated liver fractions. 4. No marked species or sex differences were observed in the absorption, disposition and metabolism of levetiracetam. 5. The hydrolysis of levetiracetam is carried out by an enzymatic process characterized by a broad tissue distribution. In the rat, the enzyme system hydrolysing levetiracetam is not induced by phenobarbital, at least under the experimental conditions used herein, whereas the enzyme system(s) involved in the other metabolic pathways is induced.
引用
收藏
页码:281 / 300
页数:20
相关论文
共 27 条
  • [11] Effects of levetiracetam, a novel antiepileptic drug, on convulsant activity in two genetic rat models of epilepsy
    Gower, AJ
    Hirsch, E
    Boehrer, A
    Noyer, M
    Marescaux, C
    [J]. EPILEPSY RESEARCH, 1995, 22 (03) : 207 - 213
  • [12] THE EFFECTS OF PHENOBARBITAL, 3-METHYLCHOLANTHRENE AND BENZO(A)PYRENE ON THE HYDROLYSIS OF XENOBIOTICS IN THE RAT
    KAUR, S
    ALI, B
    [J]. BIOCHEMICAL PHARMACOLOGY, 1983, 32 (22) : 3479 - 3480
  • [13] Evidence for a unique profile of levetiracetam in rodent models of seizures and epilepsy
    Klitgaard, H
    Matagne, A
    Gobert, J
    Wülfert, E
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1998, 353 (2-3) : 191 - 206
  • [14] LAPKA R, 1990, ACTIV NERV SUPER, V32, P58
  • [15] Löscher W, 1998, J PHARMACOL EXP THER, V284, P474
  • [16] PROFILE OF UCB-L059, A NOVEL ANTICONVULSANT DRUG, IN MODELS OF PARTIAL AND GENERALIZED EPILEPSY IN MICE AND RATS
    LOSCHER, W
    HONACK, D
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1993, 232 (2-3) : 147 - 158
  • [17] Selective blockade of N-type calcium channels by levetiracetam
    Lukyanetz, EA
    Shkryl, VM
    Kostyuk, PG
    [J]. EPILEPSIA, 2002, 43 (01) : 9 - 18
  • [18] Margineanu D. G., 2002, ANTIEPILEPTIC DRUGS, V5th, P419
  • [19] PURIFICATION AND CHARACTERIZATION OF 2 RAT-LIVER MICROSOMAL CARBOXYLESTERASES (HYDROLASE-A AND HYDROLASE-B)
    MORGAN, EW
    YAN, BF
    GREENWAY, D
    PETERSEN, DR
    PARKINSON, A
    [J]. ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 1994, 315 (02) : 495 - 512
  • [20] NICOLAS JM, 1999, P EUR S PRED DRUG ME, P193